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http://dx.doi.org/10.1016/j.ccr.2012.05.019SUMMARYIncreased transcription of ribosomal RNA genes (rDNA) by RNA Polymerase I is a common feature of human
cancer, but whether it is required for themalignant phenotype remains unclear.We show that rDNA transcrip-
tion can be therapeutically targeted with the small molecule CX-5461 to selectively kill B-lymphoma cells
in vivo while maintaining a viable wild-type B cell population. The therapeutic effect is a consequence of
nucleolar disruption and activation of p53-dependent apoptotic signaling. Human leukemia and lymphoma
cell lines also show high sensitivity to inhibition of rDNA transcription that is dependent on p53 mutational
status. These results identify selective inhibition of rDNA transcription as a therapeutic strategy for the cancer
specific activation of p53 and treatment of hematologic malignancies.INTRODUCTION
Pol I-dependent transcription of the 47S rDNA dynamically
responds to growth signaling and cellular stresses to establish
the abundance of the ribosomal RNAs and directly regulatesSignificance
Morphologic abnormalities of the nucleolus, the site of riboso
have been recognized as diagnostic for cancer for over a centu
the accelerated ribosome biogenesis responsible for the nucle
definitive evidence, both genetic and pharmacologic, that acce
sary for oncogenic activity. Further, we show that Pol I transcrip
through the nongenotoxic activation of p53-dependent apopt
Pol transcription, can serve as a therapeutic strategy for the tcellular protein translational capacity and thus proliferative
growth rate (Jorgensen et al., 2002; Larminie et al., 1998).
rDNA transcription takes place in specialized subnuclear
domains termed nucleoli that are formed around actively tran-
scribed rDNA repeats in early G1 before being disassembled inmal gene (rDNA) transcription by RNA Polymerase I (Pol I),
ry. Nevertheless, an unresolved question has been whether
olar changes is required for malignancy. Here we provide the
lerated rDNA transcription and nucleolar integrity are neces-
tion can be targeted in vivo to treat lymphoma and leukemia
osis, while sparing normal cells. Thus, selective inhibition of
reatment of cancer.
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RNA Polymerase I as a Target for Cancer Treatmentmitosis when rDNA transcription is halted. Strikingly, elevated
rDNA transcription by Pol I is a stalwart feature of cancer (Barna
et al., 2008; Ruggero and Pandolfi, 2003; White, 2005), and
enlarged nucleoli, a consequence of hyper-activated rDNA
transcription, have been used by pathologists since the late
19th century as a marker of aggressive tumors (Derenzini et al.,
2009).
In addition to rRNA and factors associated with ribosome
biogenesis, nucleoli are enriched with a large number of other
proteins, many of which have no direct function in the synthesis
of ribosomes. In many cases, regulated sequestration of these
proteins in the nucleoli controls their cellular activity. Because
of this, the nucleolus has the potential to control a broad range
of cellular functions in addition to rDNA transcription. In partic-
ular, nucleolar localization regulates the function of key onco-
genes and tumor suppressors such as ARF and MDM2, both
of which are critical for the regulation of p53 (TP53) (Boisvert
et al., 2007). Thus, Pol I-dependent transcription and nucleolar
integrity are pivotal determinants for numerous processes
required for the excessive proliferation of cancer cells.
Surprisingly, despite its constant activation in cancer and
potential to control critical determinants of malignant transfor-
mation, the importance of accelerated Pol I transcription and
nucleolar integrity for cancer and their potential as therapeutic
targets, remains undefined (Ruggero and Pandolfi, 2003; White,
2005). From a clinical perspective, a key question is whether
targeted inhibition of rDNA transcription, generally considered
a ‘‘housekeeping process’’ universally required for cell growth
and proliferation, can show selectivity for killing malignant cells
over normal cells. Furthermore, it is critical to understand the
mechanism(s) by which such selectivity might be achieved and
identify the tumor types that may therapeutically respond.
MYC is a potent oncogene whose dysregulated expression
plays a significant role in human cancer development. MYC
also plays a fundamental role in the biogenesis of ribosomes
through transcriptional upregulation of 47S rRNA, and transcrip-
tion of a select group of factors involved in rRNA processing,
rRNA transport, and ribosome assembly. Due to the function
that MYC plays in regulating Pol I activity and ribosome biogen-
esis (Arabi et al., 2005; Dai and Lu, 2008; Dang et al., 2006;
Grandori et al., 2005; Grewal et al., 2005; Poortinga et al.,
2004, 2011; Shiue et al., 2009; van Riggelen et al., 2010), models
of MYC driven oncogenesis provide an ideal setting to explore
the dependencies between Pol I transcription, ribosome biogen-
esis, and cancer.
In this study, we used both genetic approaches and a small
molecule selective inhibitor of Pol I transcription (CX-5461)
(Drygin et al., 2011) to investigate the dependence of tumors
on Pol I activity in a murine model of spontaneous lymphoma
driven by MYC (Em-Myc) (Adams et al., 1985). In addition, we
explored the therapeutic potential of inhibiting Pol I transcription
in various human hematologic malignancies.
RESULTS
rRNA Transcription and Ribosome Biogenesis
Are Accelerated in Em-Myc Lymphoma Cells
To investigate the role of Pol I transcription in malignancy,
we employed a murine model of spontaneous lymphoma52 Cancer Cell 22, 51–65, July 10, 2012 ª2012 Elsevier Inc.(Em-Myc) in which MYC is overexpressed in lymphocytes
of the B lineage. This genetic model reproduces many of the
clinical aspects of Burkitt’s lymphoma in humans, including
reciprocal chromosomal translocations that juxtapose the
c-myc proto-oncogene on chromosome 8 to the immunoglob-
ulin heavy chain locus on chromosome 14, or the k or l light
chain locus on chromosomes 2 or 22 (Adams et al., 1985;
Klein, 1993). As expected from MYC’s well-defined role in
promoting growth, premalignant B220+ splenic B cells from
4- to 6-week-old Em-Myc mice had increased cell volume,
increased protein content, and highly accelerated proliferation
rates compared to B cells from wild-type littermates (Fig-
ure S1 available online) (Iritani and Eisenman, 1999). Despite
their much faster cell doubling time, the Em-Myc B cells also
exhibited higher amounts of both total RNA and ribosomal
RNA (rRNA) per cell (Figures 1A and 1B), suggesting that Pol I
transcription and cell growth were highly accelerated. Consis-
tent with these findings, B cells from Em-Myc mice exhibited
robust increases in the level of transcription of rDNA by
Pol I, as determined by measuring the abundance of pre-rRNA,
which is rapidly processed (half-life of 10–30 min) to mature
rRNA (half-life of days to weeks) and can therefore be used
as indirect measure of rRNA synthesis rate (White, 2005)
(Figure 1C).
MYC regulates transcription of rDNA through direct activation
of Pol I (Arabi et al., 2005; Grandori et al., 2005; Shiue et al., 2009)
and by transcriptionally increasing the level of the Pol I subunits
and Pol I-specific transcription factors (Grewal et al., 2005;
Poortinga et al., 2004, 2011). Consistent with this, both the
mRNA and protein abundance of key Pol I specific components
including UBF (UBTF), a factor involved in pre-initiation complex
formation and rDNA chromatin remodeling (Sanij et al., 2008),
RRN3 (also termed TIF-1A), an essential Pol I initiation factor
(Yuan et al., 2005), and POLR1B, the second largest subunit
of Pol I (Hannan et al., 1998), were all highly elevated in prema-
lignant Em-Myc transgenic B cells compared to normal B cells
isolated from wild-type littermates (Figures 1D and 1E). Further-
more, this increased expression of Pol I-specific components
was perpetuated in malignant B cells isolated from tumor
bearing Em-Myc mice, indicating the continued elevation of
this pathway with the development of lymphoma (Figure 1E).
This demonstrates that the increased levels of the Pol I factors
and rDNA transcription occur during cellular transformation
and tumor initiation and are not simply a consequence of
transformation.
Accelerated rDNA Transcription Is Required for Survival
Em-Myc Lymphoma Cells
We used RNAi-mediated knockdown of UBF and RRN3 to
examine the extent to which the increased rate of Pol I transcrip-
tion exhibited by the Em-Myc B cells was necessary for their
proliferative capacity and survival. Em-Myc lymphoma cells iso-
lated from tumor bearing mice that grow in culture and are
wild-type for p53 were retrovirally transduced with microRNA-
based short hairpins (shRNA-mirs) targeting Ubf (shUBF) or
Rrn3 (shRRN3) (Sanij et al., 2008). Coexpression of GFP allowed
for FACS-based sorting of transduced cells. Transduction effi-
ciency was titered to reduce Ubf and Rrn3 mRNA and protein
abundance in the lymphoma cells to near those found in
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Figure 1. Regulation of Pol I Transcription in
Transgenic Em-Myc B Cells
(A) Premalignant B220+ splenic B cells were iso-
lated from premalignant (4- to 6-week-old) Em-Myc
mice (+TG) and their respective wild-type litter-
mates (WT), lysed, and total RNA content per cell
determined (p < 0.01, n = 3).
(B) Total 18S (p < 0.01, n = 3) and 28S (p < 0.05,
n = 3) rRNA per cell, as determined using an Agilent
Bioanalyzer.
(C) Pre-rRNA expression determined by quantita-
tive reverse transcription real-time (qRT) PCR of
the internally transcribed spacer 1 (ITS1) (+742
to +874) of the 47S pre-rRNA (p < 0.05; n = 5).
(D) Relative mRNA expression of Pol I transcription
factors Ubf, Rrn3, and Polr1b, determined by
qRT-PCR (Ubf, p < 0.001; Rrn3, p < 0.01; Polr1b,
p < 0.01; n = 5).
(E) Western blot analysis of ACTIN, c-MYC and Pol
I transcription factors, UBF, RRN3 and POL1RB
in premalignant and malignant (tumor bearing)
B220+ B cells isolated from +TG mice and
their respective WT littermates. Student’s two-
tailed t test for all comparisons. Error bars repre-
sent SEM.
See also Figure S1.
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UBF or RRN3 resulted in a reduction in Pol I transcription by
35%–40%, but notably, not below levels observed in normal B
cells (Figures 2C and 2D). To gauge the effect of normalizing
Pol I transcription on the proliferation and survival of Em-Myc
lymphoma cells we performed an in vitro GFP competition
assay in which mock transduced Em-Myc lymphoma cells were
mixed with equal numbers of Em-Myc lymphoma cells trans-
duced with either LMS vector alone (adapted from Dickins
et al., 2005), (Em-Myc/LMS), LMS-shUBF (Em-Myc/LMS-shUBF),
or LMS-shRRN3 (Em-Myc/LMS-shRRN3) and maintenance ofCancer Cell 22, 5the transduced population was followed
by FACS. Em-Myc/LMS-shUBF and
Em-Myc/LMS-shRRN3 cells exhibited a
profound disadvantage with regard to
proliferation and/or survival (Figure 2E).
Likewise, expression of shUBF and
shRRN3 caused an increased sub-G1
population (Figure 2F) and a 2–3-fold
increase in markers of apoptosis in-
cluding loss of mitochondrial membrane
potential (decrease in tetramethylrhod-
amine ethyl [TMRE] retention; Fig-
ure S2A) and increased AnnexinV/PI
staining (Figure S2B). This suggested
that the Em-Myc lymphoma cells were
eliminated by apoptosis following
normalization of Pol I transcription levels.
Consistent with the survival disadvantage
resulting from an induction of apoptosis,
enforced expression of the anti-apoptotic
protein BCL-2 (Figure S2C) significantly
reduced the disadvantage of the Em-Myc/LMS-shUBF and Em-Myc/LMS-shRRN3 cells (Figure 2G).
Moreover, a long-term competition assay with Em-Myc/LMS-
shRRN3 cells expressing BCL2 demonstrated that their prolifer-
ative capacity was similar to control cells (Figure S2D). These
results reveal that a 35% reduction in Pol I transcription in
Em-Myc lymphoma cells results in induction of apoptosis that
is not linked to a reduction in proliferation rate. Together these
data demonstrate that the process of malignant transformation
and cancer cell survival is considerably more dependent upon
maintenance of elevated levels of Pol I activity than previously
appreciated.1–65, July 10, 2012 ª2012 Elsevier Inc. 53
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Figure 2. Reducing Pol I Transcription
Rates in Em-Myc Lymphoma Cells Using
shRNA-mirs Against UBF or RRN3 Strongly
Activates Programmed Cell Death
(A) Western blot analysis of UBF in cultured in Em-
Myc lymphoma cells transduced with one of two
independent shRNA-mirs targeting UBF (shUBF-1
and -2) or empty vector (LMS), and in B220+
splenic B cells isolated from 4- to 6-week-old Em-
Myc mice (+TG) and their respective wild-type
littermates (WT). Relative Ubf mRNA expression
determined by qRT-PCR (LMS versus shUBF-1,
p < 0.001; LMS versus shUBF-2, p < 0.001; n = 3).
(B) Western blot analysis of RRN3 as for UBF in (a)
utilizing two independent shRNA-mirs targeting
RRN3 (shRRN3-1 and -2). Relative Rrn3 mRNA
expression determined by qRT-PCR (LMS versus
shRRN3-1, p < 0.001; LMS versus shRRN3-2,
p < 0.001; n = 4).
(C) 47S pre-rRNA synthesis determined by [32P]
orthophosphate labeling in cells transduced with
shRNA-mirs targeting UBF or RRN3 as compared
to LMS alone (representative of n = 2).
(D) Pre-rRNA expression determined by qRT-PCR
of the ITS1 in cells transduced with select shRNA-
mirs and B cells described in (a) (LMS versus
shUBF-2, p < 0.01; LMS versus shRRN3-1, p <
0.01; n = 4).
(E) GFP competition assay of GFP+, transduced
Em-Myc lymphoma cells (LMS, shUBF, shRRN3)
cocultured with GFP, mock transduced Em-Myc
lymphoma cells. Data expressed as fold change in
percentage of GFP+ cells compared to Day 2
posttransduction (n = 3).
(F) Percentage of apoptotic cells determined by
subG1 DNA content analysis expressed as fold
change over LMS (6.3% ± 0.61 SEM) (LMS versus
shUBF-1, p < 0.01; LMS versus shUBF-2, p <
0.001; n = 3) (LMS versus shRRN3-1, p < 0.05;
n = 6). See also Figures S2A and S2B.
(G) GFP competition assay in Em-Myc lymphoma
cells with BCL2 overexpression, expressed as fold
change in percentage of GFP+ cells on Day 4
compared to Day 2 posttransduction (shRRN3-
1 p < 0.01; n = 3). One-way ANOVA with Tukey’s
multiple comparison posttest (a,b,d,f). Student’s
two-tailed t test (g). Error bars represent SEM. See
also Figures S2C and S2D.
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Induces p53-Dependent Apoptotic Cell Death of Em-Myc
Lymphoma Cells
The profound sensitivity of Em-Myc lymphoma cells to reductions
in Pol I transcription led us to question whether this could be
exploited therapeutically to treat B cell lymphoma. To test this
approach, we utilized a highly selective agent (CX-5461) that
inhibits Pol I-driven transcription in the low nanomolar range by
preventing the association of the Pol I-specific transcription
initiation selectivity factor SL-1 with the rDNA promoter, exhibit-
ing >200-fold selectivity relative to the inhibition of Pol II-driven
transcription (Drygin et al., 2011). Em-Myc lymphoma cells that
had been isolated from tumor-bearing mice and cultured
in vitro were exquisitely sensitive to CX-5461 with an IC50 of
27.3 nM ± 8.1 nM for Pol I transcription after 1 hr (Figures 3A,54 Cancer Cell 22, 51–65, July 10, 2012 ª2012 Elsevier Inc.3B, S3A, and S3B) and IC50 of 5.4 nM± 2.1 nM for cell death after
16 hr (Figure 3C). Under these conditions, transcription of the Pol
II-dependent gene, b2m,was not affected (Figure S3C), attesting
to the selectively of CX-5461 for Pol I.
Loss or mutations of p53 or ARF are frequent lesions in
Em-Myc driven lymphomagenesis (Eischen et al., 1999), so we
tested a panel of Em-Myc lymphomas with variable p53 and
ARF status for sensitivity to CX-5461. We observed that the
ability of CX-5461 to kill lymphoma cells at low nM concentra-
tions (IC50 < 10 nM) was dependent on intact p53 pathway but
independent of ARF, which is frequently associated with onco-
genic stress-dependent activation of p53. Cells, mutant or null
for p53 exhibited a 180-fold decreased sensitivity to CX-5461
(Figure 3C). Importantly this was not due to elevated basal rates
of Pol I transcription as the Em-Myc clones on the different
A B C
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Figure 3. CX-5461 Induces Rapid, p53-Dependent, Apoptotic Cell Death of Em-Myc Lymphoma Cells
(A) 47S pre-rRNA synthesis in cultured Em-Myc lymphoma cells treated with increasing nM concentrations of CX-5461, determined by [32P] orthophosphate
labeling (representative of n = 3). See also Figure S3A.
(B) Pre-rRNA expression determined by qRT-PCR in cells treated with 50 nm CX-5461 as compared to vehicle alone (p < 0.01; n = 3). See also Figures S3B
and S3C.
(C) CX-5461 cell death curve of cultured Em-Myc lymphoma cell lines (including wild-type [WT], mutant [MT], and homozygous deleted [/] for indicated genes)
16 hr posttreatment, quantified by percentage of cells incorporating PI (representative of n = 3). See also Figures S3D and S3E.
(D) Induction of apoptosis in cultured Em-Myc lymphoma cells treated with 50 nM CX-5461, shown by loss of TMRE staining; increased Annexin V/PI costaining;
increased cells with subG1 DNA content. See also Figures S3F–S3H.
(E) CX-5461 cell death curve of a p53WT Em-Myc lymphoma cell line overexpressing BCL2 at 16 hr posttreatment, quantified by percentage of cells incorporating
PI (representative of n = 2).
(F) Pre-rRNA expression in an Em-Myc lymphoma cell line overexpressing BCL2 in comparison to vector alone (MSCV), and treated with 100 nM CX-5461 as
compared to vehicle as determined by qRT-PCR (n = 1). Student’s two-tailed t test for all comparisons. Error bars represent SEM.
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prior to treatment (Figure S3D). Moreover, consistent with our
previous study demonstrating that CX-5461 is nongenotoxic,
Em-Myc lymphoma cells null for ATM, amediator of DNA damage
response, exhibited a comparable level of sensitivity to CX-5461
as Em-Myc lymphoma cells wild-type for ATM and p53
(Figure S3E).
Cell death in p53wild-type lymphoma cells in response to CX-
5461 was rapid and concomitant with induction of apoptotic
markers, including progressive loss of mitochondrial membrane
potential, increased AnnexinV/PI staining, and an increased
percentage of cells with subG1 DNA content (Figures 3D and
S3F–S3H). Enforced expression of BCL-2 in p53 wild-type Em-
Myc cells reduced the cell death sensitivity to CX-5461 by over
130-fold despite exhibiting comparative inhibition of Pol I tran-
scription (Figures 3E and 3F). Thus, repression of Pol I transcrip-
tion in Em-Myc lymphoma cells by a small molecule inhibitor of
Pol I induces rapid p53-dependent cell death by apoptosis.
Inhibition of Pol I Transcription by CX-5461 Induces
p53-Mediated Death of Lymphoma Cells via Activation
of the Rp-MDM2-p53 Nucleolar Surveillance Pathway
As Pol I transcription rates ultimately determine ribosome
levels, it was possible that the apoptotic death of the Em-Myc
lymphoma cells in response to suppression of Pol I transcription
was an indirect response to ribosome insufficiency and thus
defects in translation. Indeed, a recent study demonstrated
that aberrant translation downstream of MYC hyperactivation
is required for MYC’s oncogenic potential (Barna et al., 2008).
Alternatively, acute perturbations related to many aspects
of ribosome biogenesis have been shown to contribute to
a ‘‘nucleolar stress response,’’ also called the nucleolar surveil-
lance pathway, which leads to rapid activation of p53, in an
ARF-independent manner, and induction of apoptosis well
before ribosome insufficiency and translation defects can occur
(Boisvert et al., 2007; Boulon et al., 2010; Deisenroth and
Zhang, 2010; Lohrum et al., 2003; Macias et al., 2010; Zhang
et al., 2003). We examined these mechanisms and found that
induction of apoptotic signaling was an immediate response to
repression of Pol I transcription and not driven by ribosome
insufficiency.
Treatment of Em-Myc lymphomas with CX-5461 for as little as
1 hr increased p53 levels followed by transactivation of p53
target genes, p21 (Cdkn1a) and Puma (Bbc3), and cleavage
and activation of CASPASE 3 (CASP3) at 2 hr (Figures 4A, 4B,
and S4A), despite the fact that total RNA levels, which reflect
ribosome abundance, were not decreased at these time points
(Figure 4C). Notably, neither levels of MYC protein or expression
of the MYC transcriptional targets ornithine decarboxylase 1
(Odc1) and mTert were affected, demonstrating that the cell
death was not due to alterations in MYC activity (Figures 4A
and 4B). These findings are consistent with the induction of
apoptosis being a direct result of disruption of Pol I transcription,
and activation of nucleolar stress, rather than an indirect effect
of ribosome insufficiency. To further examine this mechanism
we monitored nucleolar integrity using a prototypical nucleolar
marker protein fibrillarin (FBL), nucleophosmin (B23), and
nucleolin (NCL), which demonstrate both nucleolar and nuclear
localization, and by fluorescence in situ hybridization (FISH) for56 Cancer Cell 22, 51–65, July 10, 2012 ª2012 Elsevier Inc.the 47S rDNA repeats. Within 1 hr of treatment with 50 nM CX-
5461, the multiple nucleoli normally found in Em-Myc lymphoma
cells had fused to form a single nucleolus per cell that exhibited
reduced FBL staining (Figure 4D). Further analysis revealed that
the altered FBL staining was accompanied by relocalization of
a proportion of B23 and NCL to the periphery of the single
nucleoli (Figure S4B). This correlated with condensation of the
rDNA within the nucleoli to punctate foci, which is characteristic
of a reduced Pol I transcription rate (Figures 4E and S4C)
(McStay and Grummt, 2008). Activation of p53 by the Rp-
MDM2-p53 nucleolar surveillance pathway has been attributed
in part to the release of ribosomal proteins (RP), in particular
RPL5 and RPL11, from the nucleolus and their binding to
MDM2, a p53 E3 ubiquitin ligase. This results in the release of
p53 from MDM2 and the subsequent accumulation of p53
(Deisenroth and Zhang, 2010). To test if CX-5461 acts, in part
through the nucleolar surveillance pathway to activate p53,
we immunoprecipitated MDM2 from Em-Myc lymphoma cells
following CX-5461 treatment and examined the levels of RPL5
and RPL11 that coimmunoprecipitated with MDM2. Because
MDM2 is a transcriptional target of p53, it was important to avoid
possible confounding effects of increased levels of immunopre-
cipitated MDM2. A time course following treatment of cells with
CX-5461 demonstrated that MDM2 expression increased
dramatically beyond the 1 hr time point (Figure S4D); therefore
we performed the coimmunoprecipitation experiments after
1hr treatment, prior to changes in MDM2 levels. Consistent
with a nucleolar surveillance mechanism, coimmunoprecipita-
tion experiments demonstrated an increase in the amount of
RPL5 and RPL11 associated with MDM2 in p53 wild-type Em-
Myc lymphoma cells in response to 1 hr treatment with CX-
5461 relative to vehicle-treated cells (Figure 4F). Together with
the data shown in Figures 1, 2, and 3, these findings provide
independent lines of evidence for an absolute dependence of
Em-Myc lymphoma cells on high rates of Pol I transcription for
their survival, whereby perturbations in rRNA synthesis result in
immediate induction of a nucleolar stress response leading to
p53-dependent apoptotic cell death.
Inhibition of Pol I Transcription by CX-5461 Selectively
Induces p53-Mediated Cell Death of Lymphoma Cells
In Vivo while Sparing Normal B Cells
We next examined whether inhibition of Pol I transcription and
thus activation of the Rp-MDM2-p53 nucleolar stress pathway
could be used to selectively kill malignant B cells in vivo.
C57BL/6 mice with established disease from transplanted Em-
Myc lymphoma that is wild-type for p53 (Clone 4242) were
treated with a single oral dose of CX-5461 (50 mg/kg) or vehicle.
The Em-Myc tumor cells infiltrating the lymph nodes showed
marked sensitivity to CX-5461, with cells exhibiting an 84%
repression in Pol I transcription at 1 hr posttreatment (Figure 5A),
also confirmed by RNA chromogenic in situ hybridization (CISH)
for 47S pre-rRNA levels in the spleen (Figures S5A and
S5B). Moreover, CX-5461 induced a rapid reduction in tumor
burden in the lymph nodes (3.1% GFP-tagged malignant
cells ± 0.20 for CX-5461-treated versus 34%GFP-taggedmalig-
nant cells ± 5.5 for vehicle-treated mice at 24 hr post therapy,
p < 0.01) (Figures 5B and S5C) and a concomitant reduction
of spleen size to within the normal range (0.14 g ± 0.01 for
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Figure 4. CX-5461 Activates p53 via the Nucleolar Stress Response in Em-Myc Lymphoma Cells
(A) Western blot analysis over 3 hr of cleavage of CASPASE 3 (CASP3), total p53, p21, and c-MYC in a p53 wt wild-type Em-Myc lymphoma cell line treated with
50 nM CX-5461 in culture. See also Figure S4A.
(B) Relative p21, Puma, Odc1, and mTert mRNA expression determined by qRT-PCR (n = 3).
(C) Total RNA per cell (p > 0.05; n = 3) in cells from (a) at 1 hr of CX-5461 treatment.
(D) Nucleolar disruption shown in cells from (a) by fibrillarin (FBL) immunofluorescence with DAPI counterstain, nucleoli indicated by white arrows. See also
Figure S4B.
(E) rDNA fluorescent in situ hybridization (FISH) with DAPI counterstain 2 hr post CX-5461 treatment. See also Figures S4C and S4D.
(F) Coimmunoprecipitation of ribosomal proteins L5 (RPL5) and L11 (RPL11) with MDM2 (as compared to GFP control) in vehicle-treated Em-Myc lymphoma cells
overexpressing BCL2 cells versus cells treated with 500 nM CX-5461, as shown by western immunoblot (IB) analysis. Images taken at 603magnification. Scale
bar represents 10 mm. Student’s two-tailed t test for all comparisons. Error bars represent SEM. See also Figure S4D.
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Figure 5. Therapeutic Administration of CX-5461 Selectively Kills Transplanted p53 Wild-type Em-Myc Lymphoma Cells In Vivo
(A) Pre-rRNA expression in tumor bearing lymph nodes of mice transplanted with p53 wild-type Em-Myc lymphoma cells (clone 4242) 1 hr posttreatment with
50 mg/kg CX-5461, determined by qRT-PCR (p < 0.05; n = 4). See also Figures S5A and S5B.
(B) FACS analysis of tumor burden in lymph node; stained with antibody against pan B cell marker B220, tumor cells GFP+ (green) (representative of n = 3). See
also Figure S5C.
(C) Mean spleen weight ± SEM at 24 hr post therapy (p < 0.001; n = 3). Scale bar represents 1 cm.
(D) Western blot analysis at 6 and 24 hr of cleavage of CASP3, total p53, and p21 in the lymph node.
(E) Quantitation of apoptotic cells in lymph node, determined by subG1 DNA content analysis (vehicle versus CX-5461, p < 0.001 at 6 hr, p < 0.01 at 24 hr; n = 3).
See also Figure S5D.
(F) Hematoxylin and eosin (H&E) and TUNEL stained lymph node sections at 6 hr post therapy; images taken at 403magnification. Scale bar represents 50 mm.
Student’s two-tailed t test (a). One-way ANOVA with Tukey’s multiple comparison posttest (c,e). Error bars represent SEM.
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24 hr posttherapy, p < 0.001) (Figure 5C). Consistent with the
in vitro studies, reduction in malignant B cell numbers in vivo in
response to CX-5461 therapy was preceded by the rapid activa-
tion of p53 and p21 and markers of apoptosis within 6 hr of drug
administration (Figures 5D–5F and S5D).
Although CX-5461 activated p53 and induced apoptosis
among malignant cells, it did not trigger these responses in the
normal spleen cells of wild-type nontumor bearing mice (Figures
6A and 6B) and did not affect either spleen size or B cell numbers
(Figures 6C and 6D). The lack of a cytotoxic effect in normal
spleens cells was not due to lack of inhibition of Pol I transcrip-
tion as CISH demonstrated robust reductions in 47S pre-rRNA
levels in the spleens of wild-type nontumor bearing mice as
observed in tumor bearing mice (Figures 6E and S6A) Further-
more, the nucleolar integrity of normal bone marrow cells from
mice treated with CX-5461 was maintained, as determined by
FBL and B23 immunofluorescence (Figure 6F). By comparison,
exposure of nontumor bearingmice to 5Gyof g-irradiation, a clin-
ically appropriate dose for hematologic malignancies, resulted in
marked elevation of p53 levels, apoptosis, reduced spleen58 Cancer Cell 22, 51–65, July 10, 2012 ª2012 Elsevier Inc.weight, and B cell numbers (Figures 6A–6D). We also examined
the response of B220+ B cells from the spleens and bone
marrow of 4- to 6-week-old premalignant Em-Myc mice. These
cells also demonstrated profound sensitivity to CX-5461 as char-
acterized by p53 activation and markers of apoptotic cell death
(increased CASP3 cleavage and sub-G1 cells) whereas the
normal B cells from age-matched littermate mice failed to
show p53 activation or increased cell death (Figures S6B–S6E).
Together these data demonstrate the therapeutic response to
inhibition of Pol I transcription by CX-5461 in vivo is highly selec-
tive for premalignant and malignant cells, which differentiates
CX-5461 from genotoxic therapies such as g-irradiation.
To further demonstrate the therapeutic effect of CX-5461 in
this model, mice with established transplanted p53 wild-type
Em-Myc lymphoma (clone 107) were treated with three doses
of CX-5461 at 50 mg/kg once every 3 days. This regimen
significantly prolonged the survival of the tumor-bearing mice
(Figure 7A, p < 0.0001) and restored the white blood cell
count to within the normal range (Figure 7B). Indeed, the day
following the last dose of CX-5461, there were few identifiable
GFP-tagged tumor cells in the peripheral blood (Figures 7C
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Figure 6. Therapeutic Administration of CX-5461, in Contrast to g-Irradiation, Does Not Kill Normal B Cells In Vivo
(A) Western blot analysis of total p53 in tumor-bearing lymph nodes (tumor) (Figure 5) or spleen from wild-type (WT) mice (normal spleens) treated for 6 hr with
vehicle, 40 mg/kg CX-5461, or 5 Gy g-irradiation (g-Irr).
(B) Quantitation of apoptotic cells in spleens ofWTmice treatedwith vehicle, 40mg/kg CX-5461 or 5 Gy g-Irr; determined by subG1DNA content analysis (vehicle
versus g-Irr, p < 0.001; n = 5).
(C) Spleen weight of WT mice treated for 24 hr with vehicle, 40 mg/kg CX-5461 or 5 Gy g-Irr (vehicle versus g-Irr, p < 0.001; n = 5).
(D) Number of B220+ cells in WT spleen at 24 hr post therapy, as determined by FACS and comparative cell counts on whole organ suspensions (vehicle versus
g-Irr, p < 0.001; n = 5).
(E) Pre-rRNA expression in spleen fromWTmice at 1 hr posttreatment with vehicle or 40mg/kg CX-5461, as determined by CISH using an anti-sense probe to the
ITS1 (p < 0.05; n = 3 spleens, mean of six fields of comparative regions per spleen; %threshold area). See also Figure S6A.
(F) FBL and B23 immunofluorescence with DAPI counterstain on bone marrow from WT mice 1 hr posttreatment with vehicle, 40 mg/kg CX-5461, or 5 Gy g-Irr;
images taken at 603magnification. Scale bar represents 10 mm.One-way ANOVAwith Tukey’s multiple comparison posttest (b–d). Student’s two-tailed t test (e).
Error bars represent SEM. See also Figure S6.
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recipient-derived nonmalignant normal B cell population, again
indicating selective eradication of malignant disease (Figure 7C,bottom panel). Moreover, more prolonged dosing with CX-5461
also showed minimal effects on normal B cells (data not shown).
CX-5461 had no discernible adverse effect on the health of theCancer Cell 22, 51–65, July 10, 2012 ª2012 Elsevier Inc. 59
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Figure 7. Therapeutic Administration of CX-5461 Increases Survival from Transplanted p53 Wild-type Em-Myc Lymphoma
(A) Kaplan-Meier curves showing increased survival of mice transplanted with p53 wild-type Em-Myc lymphoma (clone 107) treated with three doses of CX-5461
at 50 mg/kg in comparison to vehicle (dosing day indicated by arrows) (p < 0.0001; vehicle, n = 7; drug, n = 8).
(B) White blood cell (WBC) count at 0 and 7 days poststart of therapy (Day7 vehicle versus Day7 CX5461 p < 0.001; vehicle, n = 7; drug, n = 8).
(C) FACS analysis of tumor burden as measured by GFP+ B cells (B220+) in peripheral blood at 7 days posttherapy.
(D) Quantitation of FACS analysis (c) of tumor burden in the peripheral blood at 7 days poststart of therapy (p < 0.0001; vehicle, n = 7; drug, n = 8).
(E) Percent change in body weight of mice on therapy (vehicle, n = 7; drug, n = 8). Logrank test (a). One-way ANOVA with Tukey’s multiple comparison posttest
(b,d). Error bars represent SEM. See also Figure S7.
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below that at the commencement of therapy and in comparison
to vehicle-treated mice (Figure 7E). To assess the ability of pro-
longed dosing of CX-5461 to extend survival, mice transplanted
with p53 wild-type Em-Myc tumors (clone 4242) were maintained
on continuous repeat dosing of CX-5461 at 40 mg/kg once
every 3 days (Figure S7A). This treatment regimen reproducibly
increased the average survival compared to the three repeat
dose regimen with the mice going through a stage of apparent
disease remission (no detectable tumor cells in peripheral
blood at day 7/8) before eventually relapsing (Figures S7B–
S7E). CX-5461 was also evaluated in a murine genetic model
of acute myeloid leukemia (AML1/ETO9a+Nras) that reproduces
many of the clinical aspects of leukemias in human patients that
carry AML1/ETO fusion genes (Zuber et al., 2009). As with
therapy in the Em-Myc model, transplanted AML1/ETO9a+Nras
leukemic cells showed marked sensitivity to CX-5461 in vivo,
undergoing p53-dependent apoptotic cell death within 6 hr of
treatment of a single 40 mg/kg dose of CX-5461 (Figures S7F–
S7I). This apoptotic response was comparable to 100 mg/kg
cytarabine, a cytotoxic drug frequently used in treatment of
patients with AML.60 Cancer Cell 22, 51–65, July 10, 2012 ª2012 Elsevier Inc.Inhibition of Pol I Transcription by CX-5461 Induces
Apoptotic Cell Death of Human Hematological
Malignancies with Sensitivity Correlating with p53
Mutational Status
To translate our findings with CX-5461 to human hematologic
malignancies, we evaluated CX-5461 against a genetically
diverse panel of cells derived from human hematologic cancers.
Consistent with the data from the murine models (Figure 3C),
viability assays demonstrated that human hematologic cancer
cells wild-type for p53 were significantly more sensitive to CX-
5461 (median IC50 = 12 nM) than p53 mutant cells (median
IC50 = 230 nM) (Figure 8A). Three cell lines, SR (large cell immu-
noblastic lymphoma), MV 4;11 (biphenotypic B myelomonocytic
leukemia), and K562 (chronic myelogenous leukemia) were
examined in further detail. Although all three cell lines exhibited
similar IC50 s for Pol I transcription in response to CX-5461 (Fig-
ure 8B), the cell viability IC50 for the SR and MV 4;11 cell lines
(IC50 = 5 nM and 12 nM, respectively) that are wild-type for
p53, were 10–20-fold less than for K562 cells (IC50 = 104 nM)
that carry a c.406_407insC nonsense mutation in p53 and hence
do not express a stable p53 transcript. Consistent with this, CX-
5461 induced rapid p53 accumulation and induction of the p53
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Figure 8. Human Leukemia and Lymphoma
Cell Lines Treated with CX-5461
(A) The result of 96 hr treatment with CX-5461 on
viability of human leukemia and lymphoma cell
lines with different p53 status (p < 0.0009
comparing TP53 wild-type [WT] IC50 to TP53
mutant IC50).
(B) Effect of CX-5461 on Pol I transcription in
human cancer cell lines, as determined by qRT-
PCR to the 50 externally transcribed spacer (50
ETS) region of the 47S pre-rRNA. Error bars
represent SEM.
(C) CX-5461 induces p53 and p21 in p53 WT SR
and MV 4;11 cell lines, but not in the p53 null K562
cell line, as determined by western blot analysis.
A549 cell lysates used as positive control for p53
and p21 in K562 blots (far right lane).
(D) CX-5461 induces apoptosis in p53 WT SR and
MV 4;11 cell lines, but not in the p53 null K562 cell
line, as determined by subG1 DNA content anal-
ysis. See also Figures S8A and S8B.
(E) Activity of CX-5461 in vivo against MV 4;11
xenograft model as measured by increased tumor
volume over days of therapy (n = 10). Error bars
represent SEM. See also Figure S8C.
(F) CX-5461 induces p21 in MV 4;11 xenografts,
as determined by western blot analysis of p21
normalized to ACTIN using densitometry (p <
0.001; n = 5). Student’s two-tailed t test.
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ure S8B) and subsequent induction of apoptosis as determined
by induction of a subG1 population (Figure 8D) and Caspase 3/7
activity (after 24 hr) in both the SR andMV 4:11 lines (Figure S8A).
In contrast, the p53-deficient K562 cells did not undergo
apoptosis in response to CX-5461 (Figures 8D and S8A).
To determine whether this apoptotic response of cells derived
from human hematologic malignancies following inhibition of Pol
I transcription could be translated into a therapeutic index in vivo,
MV 4:11 cells were transplanted subcutaneously into nude mice
and the effect of CX-5461 on tumor growth examined. Notably,
CX-5461 administered once weekly for 3 weeks demonstrated
potent antitumor activity (Figure 8E), was associated with
increased tumor levels of the p53 transcriptional target gene
p21 (Figure 8F), and was well tolerated (Figure S8C).
Together these studies establish that Pol I transcription can be
selectively targeted in vivo using a small molecule inhibitor of PolCancer Cell 22, 5I to preferentially eradicate hematologic
malignant cells by activation of p53, while
simultaneously maintaining a normal
populations of cells of the same lineage.
DISCUSSION
Herein we have used RNAi to the essen-
tial Pol I-specific transcription factors
UBF and RRN3 to provide robust genetic
evidence that accelerated Pol I transcrip-
tion is required for survival of malignant
cells. Specifically we have show that
reductions in rDNA transcription rate byas little as 35% result in apoptotic cell death of Em-Myc
lymphoma cells rather than slower growing tumor cells as might
be predicted. Using a newly described small molecule inhibitor
of Pol I transcription, CX-5461, we extended these findings to
demonstrate that dysregulation of the synthesis of rRNA plays
an essential role in cancer cell biology in vivo, thus providing
an important alternative approach for the treatment of malignant
diseases. One of the most striking and unanticipated findings of
these studies was the demonstration that the apoptotic death
induced by reductions in Pol I transcription occurred rapidly as
the result of immediate activation of p53 following perturbations
of the nucleolus rather than an indirect effect resulting from
reduced ribosome accumulation and defective protein transla-
tion. This is in contrast to what was previously demonstrated
in the Em-Myc lymphoma model following ribosomal protein
haploinsufficiency (Barna et al., 2008). Indeed when apoptosis
was blocked in Rrn3 knockdown Em-Myc cells, the resultant1–65, July 10, 2012 ª2012 Elsevier Inc. 61
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a proliferative disadvantage of these cells. Thus contrary to the
commonly accepted belief, rDNA transcription rates are not
always rate limiting for optimal proliferative growth of mamma-
lian cells. Our data demonstrate that MYC’s control of Pol I tran-
scription and nucleolar integrity is required for its oncogenic
potential, independent of its function in regulating ribosome
levels, protein translation, and proliferative growth. These find-
ings also lend strong support for the evolving paradigm of the
nucleolus being a key regulator of biology of the cancer cell
distinct from its role in determining the abundance of ribosomes
(Boisvert et al., 2007).
The rapid disruption of the nucleolus and subsequent induc-
tion of p53-mediated apoptotic cell death in response to CX-
5461 is consistent with induction of the nucleolar stress pathway
(also called the ribosome biogenesis surveillance/sensing
pathway) (Boulon et al., 2010; Deisenroth and Zhang, 2010;
Fumagalli et al., 2009) that acutely monitors the integrity of ribo-
some biogenesis pathway and activates p53 when the fidelity
of this complex process is dysregulated. This pathway can be
initiated by the accumulation of free ribosomal proteins following
perturbation of ribosome biogenesis (Boulon et al., 2010;
Deisenroth and Zhang, 2010) or MYC activation (Macias et al.,
2010). The release of free ribosomal proteins from the nucleolus
has been shown to sequester the p53 ligase MDM2 leading to
elevated p53 levels and to directly increase p53 translation, the
net result of which is induction of apoptosis (Boulon et al.,
2010; Deisenroth and Zhang, 2010). Thus, the ribosome surveil-
lance pathway (ribosomal protein-MDM2-p53) works indepen-
dently of ARF and functions in parallel and cooperatively with
ARF-dependent MYC oncogenic stress pathways to restrain
MYC oncogenesis (Macias et al., 2010). Most likely, not only
does impaired ribosome biogenesis act as a trigger to induce
p53, but ribosome biogenesis is also a homeostatic regulator
in normal cells, tightly linking on-going production of newly
synthesized ribosomes with p53 levels (Boulon et al., 2010;
Deisenroth and Zhang, 2010; Fumagalli et al., 2009). Here we
show how this process can be exploited as a therapeutic
strategy to selectively kill malignant cells. Moreover, as a nonge-
notoxic, cancer-specific activator of p53, CX-5461 is 300-fold
more potent at killing Em-Myc lymphoma cells (IC50 for cell death
of 5.4 nM) than Nutlin-3A, a selective small-molecule MDM2
antagonist and p53 activator (IC50 for cell death of 1600 nM,
results not shown), that is currently in clinical trials (Saha et al.,
2010).
The data herein also demonstrate that Pol I transcription can
be therapeutically targeted to selectively activate p53 and kill
malignant cells of hematologic origin in vivo while maintaining
a viable population of wild-type cells of the same lineage.
Indeed, normal B cells isolated from the bone marrow of wild-
type mice treated in vivo with CX-5461 at doses sufficient to
kill malignant Em-Myc B cells, did not exhibit disruption of their
nucleoli, activation of p53 or induction of apoptosis despite
having a significantly reduced rate of Pol I transcription. In
contrast, treatment of wild-type mice with doses of g-irradiation
similar to those used therapeutically for human hematologic
malignancies induced robust apoptotic cell death associated
with p53 activation in normal B cells. This striking tumor cell
selective activity following inhibition of Pol I transcription by62 Cancer Cell 22, 51–65, July 10, 2012 ª2012 Elsevier Inc.CX-5461 is most likely a function of the robust upregulation of
ribosome biogenesis we have shown to occur duringMYCdriven
lymphomagenesis sensitizing cells to the induction of the nucle-
olar stress pathway. The MYC-induced upregulation of rRNA
synthesis also requires a stoichiometric elevation in the levels
of ribosomal proteins in the nucleolus. Inhibition of rRNA
synthesis in cancer cells would result in excessive accumulation
of free ribosomal proteins and subsequent activation of the
nucleolar stress pathway and p53 as described above. Consis-
tent with this model, treatment of Em-Myc lymphoma cells with
CX-5461 promoted enhanced association of ribosomal proteins
L5 and L11 with MDM2 and subsequent activation of p53.
Furthermore, premalignant B cells of 4- to 6-week-old Em-Myc
transgenic mice also displayed p53-mediated increased sensi-
tivity to CX-5461 providing evidence that MYC overexpression
alone, independent of a fully malignant phenotype, may serve
to prime the nucleolar stress pathway in cells. Given that a range
of other oncogenes including PI3K, AKT, and Ras also play
important roles regulating ribosome biogenesis (Chan et al.,
2011; Hannan et al., 2003; Ruggero and Pandolfi, 2003; Stefa-
novsky et al., 2001;White, 2005), our findings indicate that selec-
tive activation of the ribosome biogenesis surveillance pathway
to activate p53 using small molecule inhibitors of Pol I is likely
to be therapeutically useful in the treatment of a wide range of
tumors in addition to those under control of MYC. Indeed, we
demonstrated that CX-5461 potently induced p53-dependent
apoptosis of non-MYC driven tumor cells in vivo using a trans-
genic model of AML in which the leukemic cells coexpress the
AML/ETO9a fusion protein with NRas. However, we note that
increased expression of MYC is common in hematologic malig-
nancies evenwhen it is not the primary driving event (for example
AML/ETO9a leukemia cells have elevated MYC levels). Thus we
cannot discount the possibility that MYC may be a common
factor in conferring sensitivity to apoptotic death in hematologic
malignancies in response to Pol I inhibition.
We also demonstrated that CX-5461 also exhibits potent anti-
growth capacity in a broad range of human hematological tumor
cell lines with sensitivity being dependent on the genetic and
functional status of p53. Importantly, p53 gene mutations are
rare at diagnosis in common cancers of hematopoietic origin
(Saha et al., 2010), suggesting that inhibition of Pol I may be
a broadly applicable therapeutic approach for treatment of
numerous human hematological cancers. In support of this,
CX-5461 demonstrated potent antitumor activity in a xenograft
model of biphenotypic B myelomonocytic leukemia. Intriguingly,
human cell lines from solid tumors do not generally demonstrate
p53 dependent apoptotic responses following Pol I transcription
inhibition (Drygin et al., 2011) but instead undergo senescence
and autophagy. This differential response highlights the dissim-
ilarity in the crosstalk between the nucleolar stress and cell death
in different types of cancer. It is possible that hematological
malignancies have a unique nucleolar biology that makes them
especially susceptible to activation of p53 and apoptotic cell
death following acute perturbations of ribosome biogenesis. In
support of this notion, mutations in genes encoding ribosomal
proteins that cause defects in ribosome biogenesis and activate
p53 is emerging as a shared paradigm among bone marrow
failure syndromes such as Diamond Blackfan Anemia (DBA)
and the acquired 5q syndrome myelodysplastic syndrome
Cancer Cell
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Together these data suggest that patients with hematologic
malignancies represent a highly sensitive population for the initial
trial of CX-5461 in humans.
In summary, our work demonstrates that hematologic tumor
cells depend upon hyperactivated rDNA transcription and
integrity of Pol I transcription for survival and this dependency
is vulnerable to perturbations that induce apoptosis via a process
that is independent of ribosome levels or effects on proliferation.
Further, we show that a selective inhibitor of Pol I transcription,
CX-5461, causes cancer-specific activation of p53 and induction
of apoptosis that results in the improvement of outcome in in vivo
models of leukemia and lymphoma.
EXPERIMENTAL PROCEDURES
Em-Myc Transgenic Mice, B Cell Purification, and Lymphoma
Cell Lines
All animal work was performed with approval from the Peter MacCallum
Cancer Centre Animal Experimentation Ethics Committee and Cylene
Pharmaceuticals’ Institutional Animal Care and Use Committee. Em-Myc
mice were maintained as heterozygote on a C57BL/6 background. Primary
B cells were purified from the spleen of transgenic mice and their wild-type
littermates with anti-B220 conjugated microbeads (Miltenyi Biotech) using
the autoMACS system (Miltenyi Biotech) according to manufacturer’s instruc-
tions. Lymphoma cell lines were generated from lymph nodes of tumor bearing
Em-Myc/+, Em-Myc/p53+/, Em-Myc/Arf+/ mice, and Em-Myc/Atm/. Cell
lines were determined as mutant for p53 via sequencing or assessment of
protein molecular weight via western blotting, in addition to exhibiting resis-
tance to etoposide. For in vivo drug studies, 1 3 105 Em-Myc lymphoma cells
were injected into the tail veins of wild-type C57BL/6 mice. Peripheral blood
was sampled by retro-orbital bleeding into 10 mM EDTA. For in vivo drug
studies with the mouse model of AML, Scott Lowe generously provided
leukemia cells isolated from the spleens of tumor-bearingmice. Leukemia cells
(1 3 106), AML1/ETO9a NRas p53 wt, or p53/, were injected into the tail
vein of irradiated (23 3 Gy) recipient C57BL/6 mice. Leukemia onset/progres-
sion was monitored by peripheral blood analysis and single dose of 40 mg/kg
CX-5461 was administrated when 40%–50% GFP+ cells in the peripheral
blood were detectable. Lymphoma cell lines were maintained in Anne Kelso
DMEM supplemented with 10% FBS, 100 mM L-asparagine (Sigma), 0.5%
b-mercaptoethanol, and penicillin/streptomycin/glutamine (GIBCO). Cell
volume was determined using a Beckman Coulter Z series. shRNA-mediated
knockdown was achieved via retroviral transduction as described (Schmitt
et al., 2000) using the CSHL vector system LMS (Dickins et al., 2005) with
the short-hairpin sequences listed in Supplemental Experimental Procedures.
Transduced populations were selected by sorting for GFP expression on a BD
FACS Vantage SE. Bcl2 overexpression was achieved by sorting for Cherry
expression following retroviral transduction with a MSCV vector expressing
Bcl2 cDNA.
Orthophosphate Labeling
Lymphoma cells (1.5 3 106) were cultured in 3 ml media in the presence of
500 mCi of 32P orthophosphate for 20 min. Cells were harvested on ice and
RNA extracted using the QIAGEN RNAeasy kit, according to the manufac-
turer’s instructions. RNA (7 mg) was run overnight on a 1.2% MOPS/formalde-
hyde agarose gel. The gel was dried using a Bio-Rad gel dryer, exposed
overnight to a phospho imager screen and scanned using a Typhoon TRI vari-
able mode imager (GE Healthcare). The radioactivity of each band was deter-
mined using the Image Quant TL software (GE Healthcare).
Immunofluorescence and FISH
For immunofluorescence, cells were fixed in a 2% paraformaldehyde suspen-
sion and spun onto slides. Cells were stained with antibodies listed in Supple-
mental Experimental Procedures followed by the appropriate secondary,
either 594 conjugated goat anti-rabbit IgG (Molecular Probe, A21442) or 488
conjugated goat anti-mouse IgG1 (Jackson ImmunoResearch Laboratories).Stained cells were fixed again with 4% formaldehyde, counterstained with
DAPI, and visualized on an Olympus BX-51 microscope, with images captured
using the SPOT Advance image acquisition software (Diagnostic Instruments).
For FISH, 1 mg of BAC clone (RP23-225M6) was biotin-labeled using a nick
translation kit (Roche), according to the manufacturer’s instructions. Labeled
probe (100 ng) was precipitated in ethanol together with 30 mg salmon sperm
DNA and 18 mg COT1 carrier DNA (Invitrogen) and dissolved in 30 ml hybridiza-
tion buffer (50% formamide, 20% dextran sulfate in 23 SSC). Probes were
denatured at 95C for 5 min then incubated at 37C for 1 hr. Cells were fixed
in paraformaldehyde and spun onto slides as described above. Slides were
fixed in methanol/acetic acid (3:1) for 5 min at room temperature and dried
then dehydrated through an ethanol series. Slides were incubated in 70%
formamide/23 SSC for 10 min at 83C and then dehydrated through an
ethanol series. Slides were hybridized overnight at 37C in a humidified
chamber and then washed in 50% formamide/23 SSC at 42C for 15 min
and 0.13 SSC at 60C for 15 min. Streptavidin-Alexa fluor 488 was added
for 1 hr at 37C and slides were then washed in 0.05% Tween-20/43 SSC
for 15 min. Slides were mounted in DAPI and microscopy was performed as
above. Quantitation was performed using MetaMorph (Molecular Devices,
Sunnydale, CA).
Histology
Harvested tissues were fixed in 10% neutral buffered formalin overnight
followed by paraffin wax embedding. Hematoxylin and eosin staining (H&E)
was performed on 4 mm sections. TUNEL staining was performed on 4 mm
sections using an Apoptag Peroxidase In Situ Apoptosis Detection kit
(Chemicon, S7100), according to the manufacturer’s instructions. For CISH,
4 mm sections were dewaxed in xylene followed by an ethanol series. Epitope
recovery was performed with incubation at 120C in 10 mM sodium citrate
(pH 6.0) followed by the addition of proteinase K (12.5 ng/ml) and finally, fixa-
tion in formaldehyde (4%). Hybridization was performed overnight at 37C
with digoxigenin-labeled oligonucleotide rRNA anti-sense probe to the ITS1.
Sense probe hybridization was performed under identical conditions on serial
sections as a negative control. Sections were incubated with anti-Digoxigenin-
alkaline phosphatase (Roche, 11093274910) and signal was detected in
100 mM NaCl, 100 mM Tris (pH 9.5) buffer containing 0.18 mg/ml BCIP,
0.34 mg/ ml NBT (Roche, 11 681 451 001), and 240 mg/ml levamisole (Sigma).
Tissues were counter stained with nuclear fast red stain. Sections were visu-
alized on an Olympus BX-51 and images captured using the SPOT Advance
image acquisition software. Quantitation was performed using MetaMorph
(Molecular Devices).
MV 4;11 Xenograft Model
Female immunocompromised mice CrTac:Ncr-Foxn1nu (6–8 weeks old) were
obtained from Taconic Farms (Germantown, NY). Animals were maintained
under clean room conditions in sterile filter top cages. Animals received sterile
rodent chow and water ad libitum. All procedures were conducted in accor-
dance with the Institute for Laboratory Animal Research Guide: The Care
and Use of Laboratory Animals. Xenografts were initiated by subcutaneous
injection of 53 106MV 4;11 cells into the right hind flank region of eachmouse.
When tumors reached a designated volume of 150 mm3, animals were
randomized and divided into Vehicle (50 mM NaH2PO4, pH 4.5) or CX-5461
treatment groups of 10 mice per group. CX-5461 was administered intraperi-
toneally once a week at 125 mg/kg for the length of 25 days. Tumor volumes
and body weights were measured twice weekly. The length and width of the
tumor were measured with calipers and the volume calculated using the
following formula: tumor volume = (length3width2)/2. Tumor growth inhibition
(TGI) was determined on the last day of study according to the formula:
TGI (%) = [100  (VfD  ViD)/(VfV  ViV) 3 100], where ViV is the initial mean
tumor volume in vehicle-treated group, VfV is the final mean tumor volume in
vehicle-treated group, ViD is the initial mean tumor volume in drug-treated
group, and VfD is the final mean tumor volume in drug-treated group.
SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
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